BridgeMD
Immunogenicity of 9-valent HPV vaccine in immunocompromised children and adolescents
EU CTIS ID: 2022-501413-31-00
What this study is testing
To evaluate the immunogenicity of 9vHPV vaccine in immunocompromised children and adolescents. Seroconversion from baseline to month 7 following the three doses schedule recommended for children and adolescents (over 9 years of age) will be evaluated among vertically HIV-infected children and adolescents, SOT/HSCT recipients and post-chemotherapy patients (PCT) and compared to healthy controls
- Phase III and phase IV (Integrated)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Children or adolescents 9 to <18 years of age
- Willing to sign consent/assent form
- If HIV positive, under ART and undetectable viral load and CD4 cell count >200/mm3 (at least 6 months)
- If the patient has received chemotherapy or is a SOT/HSCT recipient, referred for immunizations after adequate immune reconstitution according to routine clinical practice
You likely can't join if
- Previous history of warts and/or anal cancer.
- Previous immunization with any HPV vaccine.
- Age below 9.
- Patients who for any reason should not be included in the study according to the evaluation of the research team.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 0-17 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.